# Which question reached the instrument?

> The test desk | Peptide Laboratory Evidence Review — Compare findings at Peptide Laboratory Evidence Review: chemical identity, serial GH tests, fat scans, MOTS-c blood associations and receptor experiments.

**The comparison desk**

The comparison starts with a question, then looks for the study that actually asked it.

## Identity, duration, location and risk

The seized-sample paper [identified CJC-1295](https://doi.org/10.1002/dta.233). The hormone studies [measured its prolonged biological response](https://pubmed.ncbi.nlm.nih.gov/16352683/). Those are distinct accomplishments even when the peptide name stays the same. Comparing questions gives me firmer footing than a single ranking of compounds.

| Question | Material or population | Measurement and result |
| --- | --- | --- |
| What was in the sample? | An unknown seized preparation | [LC-MS/MS identified CJC-1295](https://doi.org/10.1002/dta.233). The answer concerned that preparation. |
| How long did the response last? | Healthy adults given long-acting CJC-1295 | [Repeated blood tests found prolonged GH and IGF-1 elevations](https://pubmed.ncbi.nlm.nih.gov/16352683/). |
| Where did fat change? | Adults with HIV and abdominal fat accumulation | [Tesamorelin changed visceral fat and liver-fat measurements versus placebo](https://pubmed.ncbi.nlm.nih.gov/25038357/). |
| Did a blood level travel with risk? | People receiving chronic hemodialysis | [Circulating MOTS-c was associated with mortality and cardiovascular events](https://pubmed.ncbi.nlm.nih.gov/39111290/). |
| Could the receptor signals reinforce each other? | Engineered cells | [Dual-receptor activation produced a larger cAMP response](https://pubmed.ncbi.nlm.nih.gov/12446584/). The fixed blend still lacks a human trial. |

The [CJC-1295](/cjc-1295), [tesamorelin](/tesamorelin), [MOTS-c](/mots-c) and [CJC-1295 / Ipamorelin](/cjc1295-ipamorelin) pages follow those questions in detail.

## Next measurements

For CJC-1295, I’m interested in health outcomes over a period long enough to assess the consequences of sustained hormone exposure. The [preserved pulses and raised trough](https://pubmed.ncbi.nlm.nih.gov/17018654/) are a substantial pharmacology result; the clinical value remains unsettled.

For tesamorelin, the [return of visceral fat after discontinuation](https://pubmed.ncbi.nlm.nih.gov/18690162/) makes duration and long-term safety especially consequential. Its approved use and strongest trial evidence concern HIV-associated lipodystrophy. A claim about another population needs a trial in that population.

For MOTS-c, the immediate gap is human evidence on an administered peptide: how it behaves, whether it helps, and what harm occurs. The dialysis cohort measured a naturally occurring blood level. For the combination, the missing object is simpler to name: the actual fixed pair, studied against appropriate comparison groups.

I’m happy for these questions to remain different. Turning them into a single score would lose the most interesting information the experiments have already supplied.

---

An independent GH-axis evidence ledger: assay-aware, literature-bound, never a store, laboratory service, or medical recommendation.